Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics

Ni Bhaoighill, Muireann and Dunlop, Elaine A. ORCID: 2019. Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics. Cancer Drug Resistance 2019 (2) , pp. 1069-1085. 10.20517/cdr.2019.87

[thumbnail of NiBhaoighill&Dunlop Review 2019.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview


Delineating the contributions of specific cell signalling cascades to the development and maintenance of tumours has greatly informed our understanding of tumorigenesis and has advanced the modern era of targeted cancer therapy. It has been revealed that one of the key pathways regulating cell growth, the phosphatidylinositol 3-kinase/mechanistic target of rapamycin (PI3K/mTOR) signalling axis, is commonly dysregulated in cancer. With a specific, well-tolerated inhibitor of mTOR available, the impact of inhibiting this pathway at the level of mTOR has been tested clinically. This review highlights some of the promising results seen with mTOR inhibitors in the clinic and assesses some of the challenges that remain in predicting patient outcome following mTOR-targeted therapy.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: OAE Publishing
Date of First Compliant Deposit: 2 January 2020
Date of Acceptance: 26 November 2019
Last Modified: 26 Oct 2022 08:43

Citation Data

Cited 8 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics